CA
MDGL icon

Continuum Advisory’s Madrigal Pharmaceuticals MDGL Stock Holding History

Continuum Advisory’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.44K Buy
+12
New +$6.15K ﹤0.01% 1402
2025
Q2 		– Sell
-7
Closed -$2.32K – 1114
2025
Q1 		$2.32K Buy
7
+2
+40% +$657 ﹤0.01% 1305
2024
Q4 		$1.54K Hold
5
– – ﹤0.01% 1499
2024
Q3 		$1.51K Buy
5
+2
+67% +$512 ﹤0.01% 1527
2024
Q2 		$840 Buy
+3
New +$714 ﹤0.01% 1504

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Continuum Advisory's MDGL Position: Q2 2026 in Review

Continuum Advisory opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 12 shares worth $6.44K. The stake represents ﹤0.01% of the portfolio and ranks #1402 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in MDGL as recently as Q1 2025.

Continuum Advisory first reported a position in MDGL in Q2 2024 and has held it in 5 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Continuum Advisory held 12 shares of Madrigal Pharmaceuticals worth $6.44K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Continuum Advisory position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1402 holding.
  • Continuum Advisory first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.